The Russian market taken the cure “Respiros” that contains fenspiride. It is reported by RBC with reference to the order of Federal service on surveillance in healthcare (Roszdravnadzor).
The document States that the manufacturer has announced a voluntary recall of “Respiros” market for revealing lengthening of QT intervals in the electrocardiogram in patients taking “Bad”. In particular, removed the pills and syrup. The medication also withdraw the registration certificate.
It is noted that “Respiros” undesirable impact on the health of patients is not fixed. The Agency decided to withdraw the drug as a preventative measure.
On 14 February it became known that the Ministry decided to withdraw from circulation the drug “Erespal” 18 Feb 2019. It was noted that the active substance of the medication, fenspiride, may cause cardiac arrhythmia. The losses from the ban “Erespal” was estimated at 2.5 billion rubles in annual revenues.